The Benchmark Company raised the price target for the Trillium Therapeutics Inc. (NASDAQ:TRIL) stock to “a Buy”. The rating was released on April 14, 2021. The research report from H.C. Wainwright has upgraded the stock from Neutral to Buy, with a price target set at $16.50. The stock was initiated by Craig Hallum, who disclosed in a research note on August 17, 2020, to Buy and set the price objective to $15.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.83 during the last quarter as opposed to a consensus estimate of -$0.91, which indicates the company beat its estimate by $0.08, which implies that the company surprised the market by 8.80%. It appears that the average earnings per share estimate for the current quarter (ending in Dec 2017) is -$0.9. This is an average of 3 analysts’ earnings, where the high earnings per share estimate is -$0.73 and the low earnings per share estimate is -$1.19.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Trillium Therapeutics Inc. (NASDAQ:TRIL) raised 0.22% to close Friday’s market session at $9.23, higher as compared to yesterday’s close. The stock price fluctuated between $9.105 and $9.41 throughout the trading session with the volume trading being 1468704 shares, which represented a significant variation when compared to the three months average volume of 1.28 million shares. The firm’s stock price fluctuated -7.52% within the last five trades and -6.39% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -30.18% in the last 6 months and -28.45% was subtracted to its value over the previous 3 months. TRIL stock is trading at a margin of -9.82%, -16.34% and -24.27% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, TRIL deals in the Healthcare domain. The stock is trading -55.96 percent below its 52-week high and 115.15 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 23.72. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Trillium Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $929.54 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 6280.70 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 3.61, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Petrova Penka, the Chief Development Officer at Trillium Therapeutics Inc. (TRIL) has sold 5,312 shares of firm on Apr 08 at a price of $11.09 against the total amount of $58910.0. In another inside trade, Uger Robert, Chief Scientific Officer of Trillium Therapeutics Inc. (NASDAQ:TRIL) sold 3,646 shares of the firm on Apr 07 for a total worth of $39450.0 at a price of $10.82. An inside trade which took place on Mar 12, Chief Scientific Officer of Trillium Therapeutics Inc. Uger Robert sold 2,917 shares of firm against total price of $34916.0 at the cost of $11.97 per share.